Global Public Health expands for better delivery of access to healthcare
Johnson & Johnson
A multidisciplinary unit with a strong business rationale for its access-to-medicine strategy.
To address unmet health needs across the world, and focuses on areas including multidrug resistant tuberculosis (MDR-TB), HIV/AIDS, neglected tropical diseases and mental health.
Operating in settings in which resources are limited can offer many barriers to access to medicine.
Johnson & Johnson represents best practice with its Global Public Health business unit dedicated to access. Launched in 2016, the unit aims to address unmet health needs across the world, and focuses on areas including multidrug-resistant tuberculosis (MDR-TB), HIV/AIDS, neglected tropical diseases and mental health. It seeks to cover all processes relating to access to medicine, from R&D to supply chains.
How is Global Public Health improving access?
Operating in settings in which resources are limited, including countries in scope of the Index, the unit works end-to-end from development to market, aiming to make access to care both responsive to need, affordable and sustainable. It has, for example, established operations in sub-Saharan African countries, with two regional offices in Kenya and Ghana. These will oversee the development and distribution of medicines for diseases that disproportionately affect those living in Africa, such as HIV/AIDS.
What makes this a best practice?
Johnson & Johnson presents a strong business rationale for its access-to-medicine strategy, consolidated in its Global Public Health unit, and has integrated this into its overall corporate strategy. Johnson & Johnson aims to scale up Global Public Health to reach more people. The unit adds clear value to access efforts, by promoting initiatives for better delivery of access to healthcare across the world, and in particular in Africa.